Building on UCSD intellectual property, EpicentRx is working on immunotherapy drugs intended to target the body's non-specific and adaptive specific immune function synchronously.
EpicentRx, a US-based cancer immunotherapy developer exploiting University of California, San Diego (UCSD) research, has procured $35m in series D funding from an unnamed client of life science-focused investment bank Biotech Alliances International.
Based in Europe, the unnamed investor will supply the cash in three tranches, bringing EpicentRx’s funding total to approximately $77m.
EpicentRx is working on two immunotherapeutic approaches each targeting a different half of the immune system – non-specific immunity and adaptive specific immunity – to…
